Treating Hepatitis C in a Primary Care setting 12.2.21
The goal of this course module is to help clinicians and other service providers understand the local and regional picture of viral hepatitis, understand HCV screening recommendations, current treatment options, the diagnosis, how to treat hcv patients, and specific issues with vulnerable populations especially people who inject drugs, the opioid use disorder.
This program is directed to primary care physicians, specialists (ID, Gastro, Hepatology), nurses, public health, Drug and Alcohol counselors, care coordinators, advocates and other allied health care workers involved in the healthcare of patients who have risk factors for Hepatitis C particularly people who inject drugs.
At course completion, attendees should be able to:
Increase HCV testing, diagnosis, counseling and treatment.
Successful linkage to HCV care will increase. Providers will understand how to diagnose and treat HCV.
Understand the effectiveness and efficacy of HCV treatment for patients and the community
· Statistics and disease burden
· Disease progression
· Extrahepatic manifestations associated with HCV
· Barriers faced by patients
· Advantages of treating in a primary care setting
· Pre-treatment assessment and evaluation
· Choosing appropriate treatment
· Preparing for treatment
· Completing a prior authorization
· Monitoring treatment
· Post treatment monitoring
· Managing advanced and complicated disease
· When to refer to specialist
Case Study Review/ Q & A
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses
Alison Kost, RN, Program Director, Community Liver Alliance
Matthew Barnes, Program Trainer, Community Liver Alliance
No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients to disclose.
Accreditation and credit designation
In support of improving patient care, this activity has been planned and implemented by the University of Pittsburgh and the Community Liver Alliance. The University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Pittsburgh School designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Healthcare Professionals
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
- 2.00 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 2.00 Attendance